ACA vs DFTX Comparison

Arcosa Inc is a manufacturer and producer of infrastructure-related products and solutions in the U.S. It operates in three segments: Construction Products, Engineered Structures, and Transportation Products. Maximum revenue is generated from the Construction Products segment, which produces aggregates, specialty materials, asphalt, and construction support gear. The Engineered Structures segment mainly manufactures and sells steel and concrete structures for infrastructure businesses, including utility structures for electricity transmission and distribution, structural wind towers, traffic and lighting structures, and telecommunication structures; and the Transportation Products segment builds inland barges, fiberglass covers, winches, marine hardware, and other industrial equipment.

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.